1+2 Might Be >2: SGLT Inhibition in Patients With Heart Failure or Chronic Kidney Disease

JACC Heart Fail. 2024 Jan;12(1):222-225. doi: 10.1016/j.jchf.2023.08.007. Epub 2023 Sep 27.

Authors

Bertram Pitt¹, Deepak L Bhatt²

Affiliations

¹ Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
² Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: dlbhattmd@post.harvard.edu.

PMID: 37768249
DOI: 10.1016/j.jchf.2023.08.007

No abstract available

Keywords: SGLT inhibition; chronic kidney disease; heart failure; sotagliflozin; type 2 diabetes.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2*
Heart Failure* / drug therapy
Humans
Hypoglycemic Agents
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

Hypoglycemic Agents